- 全部删除
您的购物车当前为空
NCT-58是一种有效的C 端HSP90抑制剂。NCT-58不会引起热休克反应(HSR)。NCT-58通过同时下调HER 家族成员以及抑制Akt 磷酸化来激发抗肿瘤活性。NCT-58杀死对曲妥珠单抗耐药的乳腺癌干细胞样细胞。NCT-58诱导HER2阳性乳腺癌细胞凋亡。


为众多的药物研发团队赋能,
让新药发现更简单!
NCT-58是一种有效的C 端HSP90抑制剂。NCT-58不会引起热休克反应(HSR)。NCT-58通过同时下调HER 家族成员以及抑制Akt 磷酸化来激发抗肿瘤活性。NCT-58杀死对曲妥珠单抗耐药的乳腺癌干细胞样细胞。NCT-58诱导HER2阳性乳腺癌细胞凋亡。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 325 | In stock | |
| 5 mg | ¥ 792 | In stock | |
| 10 mg | ¥ 1,290 | In stock | |
| 25 mg | ¥ 2,730 | In stock | |
| 50 mg | ¥ 3,830 | In stock | |
| 100 mg | ¥ 5,170 | In stock | |
| 200 mg | ¥ 6,960 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 2,190 | In stock |
NCT-58 相关产品
| 产品描述 | NCT-58 is a potent C-terminal HSP90 inhibitor. NCT-58 does not induce the heat shock response (HSR). NCT-58 elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells. |
| 体外活性 | NCT-58处理(0.1-10 μM;72小时)在HER2阳性的BT474和SKBR3细胞中增加早期和晚期凋亡细胞的数量。NCT-58处理(0.1-20 μM;72小时)呈剂量依赖性地降低HER2阳性BT474和SKBR3细胞的活力。NCT-58处理(2-10 μM;72小时)有效降低了JIMT-1和MDA-MB-453细胞中截短的p95HER2及其磷酸化形式的水平,以及Akt和磷酸化Akt(Ser473)蛋白含量的下调[1]。 |
| 体内活性 | NCT-58(30 mg/kg;i.p.;每隔一天,共47天)显著抑制肿瘤生长,并显著减少肿瘤重量。NCT-58(30 mg/kg;i.p.;每隔一天,共47天)抑制Trastuzumab耐药性肿瘤生长[1]。 |
| 别名 | NCT58 |
| 分子量 | 466.57 |
| 分子式 | C27H34N2O5 |
| CAS No. | 2411429-33-7 |
| Smiles | COc1cc(NC(=O)c2ccc3OC(C)(C)C=Cc3c2OC)ccc1OCCC1CCCCN1 |
| 颜色 | Yellow |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 40 mg/mL (85. mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容